|
JP3101690B2
(ja)
|
1987-03-18 |
2000-10-23 |
エス・ビィ・２・インコーポレイテッド |
変性抗体の、または変性抗体に関する改良
|
|
US5204244A
(en)
|
1987-10-27 |
1993-04-20 |
Oncogen |
Production of chimeric antibodies by homologous recombination
|
|
US5202238A
(en)
|
1987-10-27 |
1993-04-13 |
Oncogen |
Production of chimeric antibodies by homologous recombination
|
|
US5606040A
(en)
|
1987-10-30 |
1997-02-25 |
American Cyanamid Company |
Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
|
|
US5770701A
(en)
|
1987-10-30 |
1998-06-23 |
American Cyanamid Company |
Process for preparing targeted forms of methyltrithio antitumor agents
|
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
CA2026147C
(en)
|
1989-10-25 |
2006-02-07 |
Ravi J. Chari |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
US5961974A
(en)
|
1991-10-25 |
1999-10-05 |
Immunex Corporation |
Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
|
|
US7405270B2
(en)
|
1991-10-25 |
2008-07-29 |
Immunex Corporation |
CD40-Ligand lacking native-pattern glycosylation
|
|
US5981724A
(en)
|
1991-10-25 |
1999-11-09 |
Immunex Corporation |
DNA encoding CD40 ligand, a cytokine that binds CD40
|
|
JPH08507916A
(ja)
|
1992-06-09 |
1996-08-27 |
カイロン コーポレイション |
Ｍ−ｃｓｆの結晶化
|
|
ATE139900T1
(de)
|
1992-11-13 |
1996-07-15 |
Idec Pharma Corp |
Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
|
|
US5635483A
(en)
|
1992-12-03 |
1997-06-03 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Tumor inhibiting tetrapeptide bearing modified phenethyl amides
|
|
US5780588A
(en)
|
1993-01-26 |
1998-07-14 |
Arizona Board Of Regents |
Elucidation and synthesis of selected pentapeptides
|
|
UA40577C2
(uk)
|
1993-08-02 |
2001-08-15 |
Мерк Патент Гмбх |
Біспецифічна молекула, що використовується для лізису пухлинних клітин, спосіб її одержання, моноклональне антитіло (варіанти), фармацевтичний препарат, фармацевтичний набір (варіанти), спосіб видалення пухлинних клітин
|
|
US5773001A
(en)
|
1994-06-03 |
1998-06-30 |
American Cyanamid Company |
Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
|
|
US6239116B1
(en)
|
1994-07-15 |
2001-05-29 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
|
US6207646B1
(en)
|
1994-07-15 |
2001-03-27 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
|
US5712374A
(en)
|
1995-06-07 |
1998-01-27 |
American Cyanamid Company |
Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
|
|
US5714586A
(en)
|
1995-06-07 |
1998-02-03 |
American Cyanamid Company |
Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
|
|
JPH0967400A
(ja)
|
1995-08-31 |
1997-03-11 |
Toray Ind Inc |
モノクローナル抗体、該抗体を産生するハイブリドーマ及びその利用
|
|
AU747898B2
(en)
|
1997-03-03 |
2002-05-30 |
Bristol-Myers Squibb Company |
Monoclonal antibodies to human CD6
|
|
EP0983303B1
(en)
|
1997-05-21 |
2006-03-08 |
Biovation Limited |
Method for the production of non-immunogenic proteins
|
|
EP1019082B2
(en)
|
1997-10-02 |
2008-06-04 |
Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. |
Use of a colony stimulating factor (csf) for enhancing collateral growth of collateral arteries and/or other arteries from preexisting arteriolar connections
|
|
US6946129B1
(en)
|
1999-06-08 |
2005-09-20 |
Seattle Genetics, Inc. |
Recombinant anti-CD40 antibody and uses thereof
|
|
DE19935756A1
(de)
|
1999-07-27 |
2001-02-08 |
Mologen Forschungs Entwicklung |
Kovalent geschlossenes Nukleinsäuremolekül zur Immunstimulation
|
|
JP4307775B2
(ja)
|
1999-10-28 |
2009-08-05 |
ゼイェトホサイン・アハリネヤート |
Ｃｓｆ−１インヒビターの使用
|
|
AU767394C
(en)
|
1999-12-29 |
2005-04-21 |
Immunogen, Inc. |
Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
|
|
US7108852B2
(en)
|
2000-03-20 |
2006-09-19 |
Warner-Lambert Company Llc |
Methods of treating inflammation using antibodies to M-CSF
|
|
AR039067A1
(es)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
|
AU2003291002A1
(en)
|
2002-11-15 |
2004-06-15 |
Chiron Corporation |
Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
|
|
GB0325836D0
(en)
|
2003-11-05 |
2003-12-10 |
Celltech R&D Ltd |
Biological products
|
|
ES2605443T3
(es)
|
2003-11-06 |
2017-03-14 |
Seattle Genetics, Inc. |
Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
|
|
EP1778842B8
(en)
|
2004-07-22 |
2012-03-21 |
Five Prime Therapeutics, Inc. |
Compositions and methods of use for mgd-csf in disease treatment
|
|
WO2006096489A2
(en)
|
2005-03-08 |
2006-09-14 |
Pharmacia & Upjohn Company Llc |
Anti-m-csf antibody compositions having reduced levels of endotoxin
|
|
JP5027804B2
(ja)
|
2005-05-26 |
2012-09-19 |
シアトル ジェネティクス，インコーポレーテッド |
ヒト化抗ｃｄ４０抗体およびその使用方法
|
|
DK1907000T4
(da)
|
2005-06-08 |
2020-03-30 |
The President And Fellows Of Harvard College |
Fremgangsmåder og sammensætninger til behandling af persisterende HIV-infektioner ved hæmning af reaktionsvejen for programmeret celledød 1 (PD-1).
|
|
MX2008007140A
(es)
|
2005-12-09 |
2009-03-04 |
Seattle Genetics Inc |
Metodos para utilizar agentes de union a cd40.
|
|
US20090246208A1
(en)
|
2006-01-05 |
2009-10-01 |
Novartis Ag |
Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
|
|
US20070280935A1
(en)
|
2006-04-07 |
2007-12-06 |
Bernd Bohrmann |
Antibody that recognizes phosphorylated peptides
|
|
EP2079305A4
(en)
|
2006-12-12 |
2010-01-27 |
Idera Pharmaceuticals Inc |
SYNTHETIC AGONISTS OF TLR9
|
|
CA2673870A1
(en)
|
2006-12-27 |
2008-07-10 |
Emory University |
Compositions and methods for the treatment of infections and tumors
|
|
CA2681790A1
(en)
|
2007-03-30 |
2008-10-09 |
F. Hoffmann-La Roche Ag |
Composition of labeled and non-labeled monoclonal antibodies
|
|
EP2155238B1
(en)
|
2007-06-05 |
2016-04-06 |
Yale University |
Antibody against d4 domain of the kit receptor and use thereor
|
|
JP5718640B2
(ja)
|
2007-08-21 |
2015-05-13 |
アムジエン・インコーポレーテツド |
ヒトｃ−ｆｍｓ抗原結合性タンパク質
|
|
US8470977B2
(en)
|
2008-03-14 |
2013-06-25 |
Transgene S.A. |
Antibody against the CSF-1R
|
|
RU2547586C2
(ru)
|
2008-03-14 |
2015-04-10 |
Трансжене С.А. |
Антитело против csf-1r
|
|
WO2009120905A2
(en)
|
2008-03-26 |
2009-10-01 |
Cellerant Therapeutics, Inc. |
Immunoglobulin and/or toll-like receptor proteins associated with myelogenous haematological proliferative disorders and uses thereof
|
|
MX356367B
(es)
|
2008-12-09 |
2018-05-25 |
Genentech Inc |
Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
|
|
JP2012516352A
(ja)
|
2009-01-30 |
2012-07-19 |
イデラ ファーマシューティカルズ インコーポレイテッド |
Ｔｌｒ９の合成アゴニスト
|
|
JP5694921B2
(ja)
|
2009-04-20 |
2015-04-01 |
協和発酵キリン株式会社 |
アミノ酸変異が導入されたＩｇＧ２を有する抗体
|
|
EP3279215B1
(en)
|
2009-11-24 |
2020-02-12 |
MedImmune Limited |
Targeted binding agents against b7-h1
|
|
DK2510010T3
(en)
*
|
2009-12-10 |
2015-12-14 |
Hoffmann La Roche |
Antibodies that bind to human CSF1R extracellular domain 4 and their use
|
|
CN102918061B
(zh)
|
2010-03-05 |
2016-06-08 |
霍夫曼-拉罗奇有限公司 |
针对人csf-1r的抗体及其用途
|
|
RU2617971C2
(ru)
|
2010-03-05 |
2017-04-28 |
Ф.Хоффманн-Ля Рош Аг |
Антитела против csf-1r человека и их применение
|
|
TWI426920B
(zh)
|
2010-03-26 |
2014-02-21 |
Hoffmann La Roche |
雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
|
|
AR080698A1
(es)
|
2010-04-01 |
2012-05-02 |
Imclone Llc |
Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
|
|
EP3943154A1
(en)
|
2010-05-04 |
2022-01-26 |
Five Prime Therapeutics, Inc. |
Antibodies that bind csf1r
|
|
CN107012149A
(zh)
|
2010-11-19 |
2017-08-04 |
艾德拉药物股份有限公司 |
调控基于toll‑样受体的免疫应答的免疫调节寡核苷酸(iro)化合物
|
|
GB201021867D0
(en)
|
2010-12-23 |
2011-02-02 |
Mologen Ag |
Non-coding immunomodulatory DNA construct
|
|
LT2691417T
(lt)
|
2011-03-29 |
2018-10-25 |
Roche Glycart Ag |
Antikūno fc variantai
|
|
FR2975600B1
(fr)
|
2011-05-24 |
2013-07-05 |
Assist Publ Hopitaux De Paris |
Agents pour le traitement de tumeurs
|
|
AU2012285875B2
(en)
|
2011-07-18 |
2016-11-10 |
Morphosys Ag |
Use of c-Fms antagonists
|
|
BR112014002353B1
(pt)
|
2011-08-01 |
2022-09-27 |
Genentech, Inc |
Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit
|
|
KR102061358B1
(ko)
|
2011-10-21 |
2019-12-31 |
트랜스진 에스.에이. |
대식세포 활성화의 조절
|
|
BR112014012819B1
(pt)
|
2011-11-28 |
2022-08-16 |
Merck Patent Gmbh |
Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
|
|
MX356337B
(es)
|
2011-12-15 |
2018-05-23 |
Hoffmann La Roche |
Anticuerpos contra csf-1r humano y sus usos.
|
|
MX2014008961A
(es)
|
2012-02-06 |
2014-10-14 |
Genentech Inc |
Composiciones y metodos para utilizar inhibidores de csf1r.
|
|
AR090263A1
(es)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
|
US8993614B2
(en)
|
2012-03-15 |
2015-03-31 |
F. Hoffmann-La Roche Ag |
Substituted pyrrolidine-2-carboxamides
|
|
US20130302322A1
(en)
|
2012-05-11 |
2013-11-14 |
Five Prime Therapeutics, Inc. |
Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
|
|
KR20150018533A
(ko)
|
2012-05-11 |
2015-02-23 |
파이브 프라임 테라퓨틱스, 인크. |
콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법
|
|
CN107759690A
(zh)
|
2012-08-31 |
2018-03-06 |
戊瑞治疗有限公司 |
用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
|
|
CN104936983A
(zh)
|
2012-11-09 |
2015-09-23 |
特朗斯吉有限公司 |
对单核细胞或其前体分化的调节
|
|
AR095882A1
(es)
|
2013-04-22 |
2015-11-18 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
|
|
AR097584A1
(es)
|
2013-09-12 |
2016-03-23 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
|
|
TWI680138B
(zh)
*
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗ｐｄ-ｌ１之人類抗體
|
|
BR112017000672A2
(pt)
|
2014-07-15 |
2017-11-14 |
Genentech Inc |
composições para tratamento de câncer utilizando antagonistas de ligação de eixo pd-1 e inibidores de mek
|
|
EP3180087B1
(en)
|
2014-08-12 |
2019-03-13 |
Alligator Bioscience AB |
Combination therapies with anti cd40 antibodies
|
|
HUE054012T2
(hu)
*
|
2014-10-29 |
2021-08-30 |
Five Prime Therapeutics Inc |
Kombinációs terápia rák ellen
|
|
CN106999583A
(zh)
*
|
2014-11-17 |
2017-08-01 |
豪夫迈·罗氏有限公司 |
包含ox40结合激动剂和pd‑1轴结合拮抗剂的组合疗法
|
|
HUE053145T2
(hu)
*
|
2014-12-31 |
2021-06-28 |
Checkmate Pharmaceuticals Inc |
Kombinált tumor immunterápia
|
|
WO2016196935A1
(en)
*
|
2015-06-03 |
2016-12-08 |
Boston Biomedical, Inc. |
Compositions comprising a cancer stemness inhibitor and an immunotherapeutic agent for use in treating cancer
|
|
EP3504239B1
(en)
*
|
2016-08-25 |
2024-05-29 |
F. Hoffmann-La Roche AG |
Intermittent dosing of an anti-csf-1r antibody in combination with macrophage activating agent
|
|
CN110072553B
(zh)
*
|
2016-12-22 |
2023-09-15 |
豪夫迈·罗氏有限公司 |
在抗pd-l1/pd1治疗失败之后抗csf-1r抗体与抗pd-l1抗体组合对肿瘤的治疗
|
|
WO2018160917A1
(en)
|
2017-03-03 |
2018-09-07 |
Janssen Biotech, Inc. |
Co-therapy comprising a small molecule csf-1r inhibitor and an agonistic antibody that specifically binds cd40 for the treatment of cancer
|
|
EP3740509A4
(en)
*
|
2018-01-17 |
2022-06-22 |
Apexigen, Inc. |
Anti-pd-l1 antibodies and methods of use
|
|
HRP20260607T1
(hr)
|
2018-09-13 |
2026-06-05 |
F. Hoffmann-La Roche Ag |
Formulacija protutijela na csf-1r
|